Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.

Oliver ReichMartin K SchmidRoland RapoldLucas M BachmannEva Blozik

Published in: BMC ophthalmology (2017)

Real-life data contradicts the assumption that aflibercept is used less frequently as compared to ranibizumab. This results in similar total health care expenditures for both anti-VEGF agents.

Keyphrases

age related macular degeneration
healthcare
diabetic retinopathy
electronic health record
vascular endothelial growth factor
big data
machine learning
affordable care act
deep learning
data analysis